支气管热成形术治疗持续性哮喘10年后的安全性和有效性(BT10+):三项随机对照试验的随访研究
支气管热成形术组在BT10+访视时的重度急性发作比例与治疗后1年和5年相似,生活质量及肺功能稳定;AIR2参与者中13%有支气管扩张,7%新发支气管扩张(多为轻度)。结论认为疗效可持续10年以上,安全性可接受。
要点
- 支气管热成形术后10年以上重度急性发作比例保持稳定,疗效持久。
- 生活质量与肺功能在1年、5年和10年以上访视间相似。
- 新发支气管扩张少见且多为轻度,安全性可接受。
核心结论
- 支气管热成形术的疗效可持续10年或更久,且安全性可接受。
- 对于优化药物治疗仍控制不佳的哮喘患者,支气管热成形术是长效治疗选择。
研究设计与样本
- BT10+为国际多中心随访研究,随访既往参加AIR、RISA和AIR2试验且治疗后随访≥10年的参与者。
- 共纳入192例(占原始试验429例的45%),其中136例接受支气管热成形术(占原始试验260例的52%),56例为假手术或对照组(占原始试验169例的33%)。
- 主要有效性终点为比较治疗后第1年和第5年重度急性发作比例与BT10+访视前12个月的比例。
- 主要安全性终点为无临床显著的治疗后呼吸影像学改变(支气管扩张或支气管狭窄,经CT确认,仅AIR2参与者)。
主要发现
- 生活质量测量和肺功能在1年、5年和BT10+访视间相似。
- AIR2参与者中,接受支气管热成形术者BT10+访视时CT显示13%(13/97)有支气管扩张;基线无支气管扩张的89例中6例(7%)新发支气管扩张(5例轻度,1例中度)。
- 原始研究后接受支气管热成形术的参与者和假手术/对照组参与者在BT10+访视时重度急性发作较基线也有减少。
临床怎么用
- 对于优化药物治疗仍控制不佳的哮喘患者,可考虑支气管热成形术作为长效治疗选项。
- 长期随访中需关注重度急性发作、生活质量和肺功能变化,以及影像学支气管扩张等安全性指标。
局限性
- 仅45%的原始试验参与者纳入BT10+研究,可能存在选择偏倚。
- 影像学安全性数据仅来自AIR2参与者,样本量有限。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Bronchial thermoplasty is an endoscopic treatment for uncontrolled asthma. Previous randomised clinical trials have shown that bronchial thermoplasty reduces severe exacerbations in people with asthma. However, the long-term efficacy and safety of bronchial thermoplasty beyond 5 years is unknown. The BT10+ study aimed to investigate the efficacy and safety of bronchial thermoplasty after 10 or more years of follow-up. METHODS: BT10+ was an international, multicentre, follow-up study of participants who were previously enrolled in the AIR, RISA, and AIR2 trials and who had 10 or more years of follow-up since bronchial thermoplasty treatment. Data on patient demographics, quality of life, lung function, CT scans (AIR2 participants only), severe exacerbations, and health-care use during the previous year were collected at the BT10+ 10-year outcomes study visit. The primary effectiveness endpoint was durability of the thermoplasty treatment effect, determined by comparing the proportion of participants who had severe exacerbations during the first and fifth years after bronchial thermoplasty treatment with the proportion of participants who had severe exacerbations during the 12-month period before the BT10+ visit. The primary safety endpoint was the absence of clinically significant post-treatment respiratory image changes after bronchial thermoplasty, defined as bronchiectasis or bronchial stenosis as confirmed by pulmonary volumetric high-resolution CT scan at the BT10+ visit (AIR2 participants only). All analyses were done on an intention-to-treat basis. The trial is registered with ClinicalTrials.gov, NCT03243292. The last patient was enrolled on Dec 11, 2018. The last patient completed follow-up on Jan 10, 2019. FINDINGS: The BT10+ study enrolled 192 (45%) of the 429 participants who were enrolled in the AIR, RISA, and AIR2 trials. The BT10+ participants comprised 136 who received bronchial thermoplasty (52% of the 260 participants who received bronchial thermoplasty in the original trials), and 56 sham or control participants (33% of 169 from the original trials). 18 (32%) sham or control participants received bronchial thermoplasty after the previous trials concluded. The participants included in BT10+ were followed for 10·8-15·6 years (median 12·1 years) post-treatment. Baseline characteristics were similar between participants enrolled in BT10+ and those not enrolled. Participants treated with bronchial thermoplasty had similar proportions of severe exacerbations at the BT10+ visit (34 [25%] of 136 participants) compared with 1 year (33 [24%] of 135 participants; difference 0·6%, 95% CI -9·7 to 10·8) and 5 years (28 [22%] of 130 participants; difference 3·5%, -6·7% to 13·6) after treatment. Quality of life measurements and spirometry were similar between year 1, year 5, and the BT10+ visit. At the BT10+ study visit, pulmonary high-resolution CT scans from AIR2 participants treated with bronchial thermoplasty showed that 13 (13%) of 97 participants had bronchiectasis. When compared with baseline high-resolution CT scans, six (7%) of 89 participants treated with bronchial thermoplasty who did not have bronchiectasis at baseline had developed bronchiectasis after treatment (5 classified as mild, 1 classified as moderate). Participants treated with bronchial thermoplasty after the original study and participants in the sham or control group also had reductions in severe exacerbations at the BT10+ visit compared with baseline. INTERPRETATION: Our findings suggest that efficacy of bronchial thermoplasty is sustained for 10 years or more, with an acceptable safety profile. Therefore, bronchial thermoplasty is a long-acting therapeutic option for patients with asthma that remains uncontrolled despite optimised medical treatment. FUNDING: Boston Scientific.
引用
- Chaudhuri R, Rubin A, Sumino K, et al. Safety and effectiveness of bronchial thermoplasty after 10 years in patients with persistent asthma (BT10+): a follow-up of three randomised controlled trials. Lancet Respir Med. 2021. PMID: 33524320. doi:10.1016/S2213-2600(20)30408-2
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。